ADDvise receives allocation decision worth approximately 3 MSEK - Regulatory information
ADDvise Group AB's (publ) subsidiary Sonar Oy has received an allocation decision regarding the delivery of X-ray systems to Päijät-Häme Central Hospital in Lahti to a total value of approximately 3 MSEK. Delivery of the equipment is planned to take place during Q4 2019.
The decision is subject to an appeal time expiring July 1st 2019.
For further information, please contact:
Rikard Akhtarzand, CEO
+46 765-25 90 71
This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on June 17th 2019, 16:30 CET.
About ADDvise Group
ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group’s shares are listed on Nasdaq First North and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com